Intra-vitreal injections or implants      

FOI REFERENCE: 24092 FOI DATE: 9^th May 2024   

I am analysing the usage of intra-vitreal injections or implants by the NHS.  Could you please tell me how many of the following intra-vitreal injections/implants your trust has administered in the four-month period from January to April 2024:

• Aflibercept                                                                     1593
• Bevacizumab – Avastin                                                   94
• Bevacizumab – Biosimilar                                               0
• Brolucizumab                                                                  0
• Dexamethasone                                                              103
• Faricimab                                                                         193
• Fluocinolone acetonide                                                   7
• Ranibizumab – Lucentis (pre-filled syringes)                  31
• Ranibizumab – Lucentis (vials)                                        0
• Ranibizumab – Ongavia                                                 294